PSA levels

February 10, 2021February 10, 2021

New AI Tool May Better Predict Relapse After Surgery

News

Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called ... Read more

August 4, 2020August 4, 2020

Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer

News

Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, unilateral prostate cancer, without the common side effects of ... Read more

July 23, 2020July 23, 2020

New Risk Calculator May Help Men With High PSA Decide on Having Prostate Biopsy

News

A new risk calculator may help men with high levels of prostate-specific antigen (PSA) — a marker of prostate cancer — to decide if they should undergo a prostate biopsy ... Read more

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also highlighted ... Read more

January 13, 2020January 13, 2020

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

News

Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b clinical ... Read more

October 16, 2019October 25, 2019

Long-term Hormone Therapy Does More Harm than Good in Prostate Cancer Patients with Low PSA Levels After Surgery, Analysis Shows

News

Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they might ... Read more

September 4, 2019

Add-on Onvansertib Overcomes Resistance to Zytiga in mCRPC, Early Data Show

News

Adding the investigational oral therapy onvansertib to a regimen of Zytiga (abiraterone acetate) and prednisone overcomes resistance to Zytiga in men with metastatic castration-resistant prostate cancer (mCRPC), according to early ... Read more

July 15, 2019

Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show

News

A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in ... Read more

March 3, 2017

CyberKnife Therapy Prevents Prostate Cancer in Men at Low to Intermediate Risk, Study Says

News

Men at low risk of prostate cancer who got radiation therapy with Accuray‘s CyberKnife System were still disease-free after seven years, as were 88.5 percent of men at intermediate risk, concluded a clinical ... Read more

February 10, 2017February 10, 2017

Genetic Predictors of PSA Levels Could Boost Reliability of PSA Tests to Diagnose Prostate Cancer

News

Unravelling genetic predictors that determine a man’s natural PSA levels could help enhance the sensitivity and specificity of PSA tests as a tool for diagnosing prostate cancer, according to a recent ... Read more